A 39‐year‐old patient, suffering from severe haemophilia B and antibodies against factor IX, has twice been treated with extracorporeal protein A‐Sepharose adsorption followed by conventional substitution therapy in combination with immunosuppression (cyclophos‐phamide). On both occasions, separated by a 2‐year interval, the same procedure was followed except that, on the second, administration of i.v. immunoglobulin (Gammonativ, KabiVitrum) was added. Within a week of the first treatment the patient developed a 15‐fold increase in the antibody titre. Following the second treatment described here, no secondary antibody response could be detected, and after a further 12 weeks only traces of antibodies are demonstrable. It seems that antibody...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
International audienceTherapeutic factor VIII is highly immunogenic. Despite intensive research in t...
Intramuscular (IM) administration of an adeno-associated viral (AAV) vector represents a simple and ...
Antibodies are important protein structures in the immunological defence. Occasionally the regulatio...
Item does not contain fulltextThe development of inhibitory antibodies to factor VIII (FVIII) or fac...
The haemostatic effect of by-passing agents such as activated prothrombin complex concentrates (aPCC...
Two patients with haemophilia B and high-responding inhibitor to factor IX were subjected to immune ...
Inhibitors are antibodies directed against haemophilia treatment products which interfere with their...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
Hemophilia A patients producing antibodies towards FVIII are usually treated with infusions of high ...
Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by th...
A number of diseases are treated by passive administration of human proteins. Human coagulation fact...
International audienceIntroduction: The recent approval of emicizumab has significantly changed the ...
Intravenous IgG has been adopted as treatment for various immune-related diseases, including immune ...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
International audienceTherapeutic factor VIII is highly immunogenic. Despite intensive research in t...
Intramuscular (IM) administration of an adeno-associated viral (AAV) vector represents a simple and ...
Antibodies are important protein structures in the immunological defence. Occasionally the regulatio...
Item does not contain fulltextThe development of inhibitory antibodies to factor VIII (FVIII) or fac...
The haemostatic effect of by-passing agents such as activated prothrombin complex concentrates (aPCC...
Two patients with haemophilia B and high-responding inhibitor to factor IX were subjected to immune ...
Inhibitors are antibodies directed against haemophilia treatment products which interfere with their...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
Hemophilia A patients producing antibodies towards FVIII are usually treated with infusions of high ...
Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by th...
A number of diseases are treated by passive administration of human proteins. Human coagulation fact...
International audienceIntroduction: The recent approval of emicizumab has significantly changed the ...
Intravenous IgG has been adopted as treatment for various immune-related diseases, including immune ...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
International audienceTherapeutic factor VIII is highly immunogenic. Despite intensive research in t...
Intramuscular (IM) administration of an adeno-associated viral (AAV) vector represents a simple and ...